scholarly journals HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1150
Author(s):  
Magda Zanelli ◽  
Luca Stingeni ◽  
Maurizio Zizzo ◽  
Giovanni Martino ◽  
Francesca Sanguedolce ◽  
...  

A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and systemic medications including prednisolone, acitretin, anti-IL17 (ixekizumab), TNF inhibitor (adalimumab), anti-IL23 (guselkumab), methotrexate, cyclosporine, and phosphodiesterase 4 inhibitor (apremilast) were ineffective. Repeated skin biopsies excluded mycosis fungoides, confirming psoriasis; molecular analysis of T-cell receptor genes ruled out clonality. The axillary lymph node histology documented a dermatopathic lymphadenitis, often associated with chronic cutaneous inflammatory diseases. At an accurate morphological evaluation, features of HHV8-positive multicentric Castleman disease were observed. Moreover, in a few follicles, in situ mantle cell neoplasia was identified. The translocation t(11;14)(q13;q32), characteristic of mantle cell lymphoma, and the monoclonal IGH gene rearrangement were present. HHV8 DNA was identified on plasma sample. Multicentric Castleman disease in psoriatic patients is a rare event and it might be favored by the immunomodulatory treatment in longstanding psoriasis. Multicentric Castleman disease patients are predisposed to developing simultaneous or subsequent lymphoma. In situ mantle cell neoplasia often behaves indolently, although it may progress to overt mantle cell lymphoma. Rituximab achieved a good control of psoriasis. Unfortunately, the patient developed Staphylococcus aureus sepsis for which he is currently on antibiotic therapy.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 323-323 ◽  
Author(s):  
Frederick Racke ◽  
Sabrina Simpson ◽  
Beth Christian ◽  
Kristie A. Blum ◽  
Robert Hasserjian ◽  
...  

Abstract Abstract 323 Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma characterized by treatment failures and short survival. At presentation, MCL is often widely disseminated. Occasionally, early lymphoma can be seen as in situ lesions involving the mantle zones of secondary follicles. The primary genetic lesion involved in the pathogenesis of the disease is the t(11;14)(q13;q32)/(IGH/CCND1) which leads to the overexpression of cyclin D1, a cell cycle regulatory protein that is not normally expressed in B-cells. However, MCL frequently has numerous additional chromosomal alterations making it one of the most genetically unstable lymphomas. Thus, while the IGH/CCND1 rearrangement is the critical initiating event, it appears that additional alterations are necessary to develop MCL. However, little is known about the latency period required to accumulate sufficient lesions to develop MCL. Recently, it has been appreciated that the initiating chromosomal events in other B-cell malignancies may precede the development of overt disease by many years. In particular, the defining chromosomal events in childhood ALL may be found in the heel sticks of children at birth, even if leukemia does not develop until a number of years later. We recently reported a unique case of mantle cell lymphoma arising simultaneously in the donor and recipient 12 years following allogeneic bone marrow transplantation for chronic myelogenous leukemia(J. Clin. Oncol., in press). This suggested that MCL may exhibit long latency periods prior to the development of frank lymphoma. In order to determine whether in situ MCL may be identified in patients with MCL, we identified 7 patients who were diagnosed with mantle cell lymphoma and who had previous pathological material available that contained lymphoid tissue and that was unrelated to the subsequent MCL. Remarkably, all 7 specimens showed evidence of in situ mantle cell lymphoma, as judged by cyclin D1 over-expression localized to lymphoid cells. Pathological specimens ranged from 2.1–15.5 years prior to the diagnosis of MCL. In all 7 specimens, cyclin D1 positive collections of lymphocytes were identified, 5 with distinct homing to mantle zones, one with follicular colonization and mantle homing, and 1 with a diffuse distribution. FISH studies were undertaken to identify cyclin D1 chromosomal translocations, and evidence of chromosomal translocations could be identified in 2/3 cases evaluated whereas no signals were seen in adjacent uninvolved lymphoid tissue. Taken together, the data presented strongly suggest that a long latency period following the initiating IGH/CCND1 translocation may occur in MCL with patients harboring in situ lesions for years prior to the development of clinical disease. These findings shed interesting new light on the natural history of MCL. Pre-lymphoma location Pattern of in situ MCL Latency (yrs) Lymphoma location CCND1 FISH in pre-lymphoma specimen Obturator node from radical prostatectomy CyclinD1+ focal colonized follicles, scattered cells in mantles 7.4 Sigmoid colon biopsy ND Duodenal serosal lymph node (perforated benign gastric ulcer) Diffuse scattered CyclinD1+ cells 2.1 Sigmoid colon biopsy ND Right neck subcutaneous lymph node (neurofibroma excision) CyclinD1+ cells in follicular mantles 3.2 Bone marrow biopsy ND Periesophageal lymph nodes from esophagectomy Several CyclinD1+ colonized primary follicles 8.0 Right cervical lymph node ND Axillary lymph node from mastectomy CyclinD1+ cells in follicular mantles 15.5 Mesenteric lymph node <5% positive signals Mesenteric lymph node dissection for colon cancer CyclinD1+ cells in follicular mantles 10.6 Base of tongue lesion Positive Cervical lymph node involved with T cell lymphoma CyclinD1+ cells in follicular mantles 3.1 Right axillary lymph node Positive Disclosures: No relevant conflicts of interest to declare.


2015 ◽  
Vol 143 (2) ◽  
pp. 274-282 ◽  
Author(s):  
Caroline Sloan ◽  
Qun-Bin Xiong ◽  
Anne Crivaro ◽  
Sharon Steinman ◽  
Adam Bagg

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e18566-e18566
Author(s):  
C. M. Hamm ◽  
R. Herriot

Haematologica ◽  
2011 ◽  
Vol 97 (2) ◽  
pp. 270-278 ◽  
Author(s):  
A. Carvajal-Cuenca ◽  
L. F. Sua ◽  
N. M. Silva ◽  
S. Pittaluga ◽  
C. Royo ◽  
...  

2007 ◽  
Vol 52 (2) ◽  
pp. 256-260 ◽  
Author(s):  
N Aqel ◽  
F Barker ◽  
K Patel ◽  
K N Naresh

2018 ◽  
Vol 2018 ◽  
pp. 1-12
Author(s):  
Mingkai Zhang ◽  
Yang Gao ◽  
Jialiang Wang ◽  
Zhanbo Liu ◽  
Zaishun Jin ◽  
...  

In order to determine a particular tumor cell via nanomaterials, we introduce the preparation of CD20 and CD5 coupled nanoprobes (denoted as CD20 and CD5 nanoprobes for convenience) and an application in identification of mantle cell lymphoma (MCL) from B-cell lymphoma. In this work, CD20 and CD5 nanoprobes were prepared by selectively oxidizing the carbon-carbon double bonds of oleate ligands on the surfaces of NaYF4:Yb3+,Tm3+ and NaYF4:Yb3+,Er3+ nanoparticles and, respectively, coupling carboxyl groups on the particles’ surfaces with CD20 and CD5 monoclonal antibodies through EDC/NHS crosslinking agents. After in situ hybridized Jeko-1 cells and Raji cells as a reference with CD20 and CD5 nanoprobes, in vitro double-color upconversion fluorescence imaging of Jeko-1 cells was demonstrated through visualization of blue and green fluorescence under a 980 nm laser excitation. Moreover, in vivo upconversion fluorescence imaging of the transplanted cancer model was also measured. These experimental results indicate that Jeko-1 cells have been specifically labeled by CD20 and CD5 nanoprobes. It is therefore concluded that CD20 and CD5 nanoprobes could be used to specially differentiate mantle cell lymphoma (MCL) from B-cell lymphoma.


1996 ◽  
Vol 93 (3) ◽  
pp. 656-660 ◽  
Author(s):  
MICHELE MONTEIL ◽  
MARY CALLANAN ◽  
CRISTINA DASCALESCU ◽  
JEAN-JACQUES SOTTO ◽  
DOMINIQUE LEROUX

Sign in / Sign up

Export Citation Format

Share Document